Syncom Formulations (India) Ltd.

₹11.83

-0.1 (-0.9%)

SYNCOMF Share Price

Pharmaceuticals & Biotechnology

As on January 27, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,128 Cr

P/E Ratio22.49

Dividend YieldN/A

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	11.99	Bearish
10-DMA	12.47	Bearish
20-DMA	13.22	Bearish
50-DMA	14.47	Bearish
100-DMA	15.67	Bearish
200-DMA	17.08	Bearish

Historical Performance

1 Year

-30.7%

3 Years

52.6%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2017
Net Sales	4,650	2,634	2,243	2,197	1,848
Total Expenditure	4,109	2,337	2,044	1,996	1,683
Other Income	174	135	146	120	28
Operating Profit	716	432	345	320	193
Interest	9	45	34	19	3
Depreciation	52	47	45	39	31
Profit Before Tax	655	340	266	262	159
Consolidated Net Profit	494	253	201	198	105
Adjusted EPS	1	---	---	---	---

Compounded Sales Growth

10 Years:21.8

5 Years:16.2

3 Years:16.2

TTM:12

Compounded Profit Growth

10 Years:38.3

5 Years:20.1

3 Years:20.1

TTM:14.3

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:15.1

TTM:-29.6

Return on Equity

10 Years:N/A

5 Years:0.1

3 Years:0.2

last year:0.5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2017
Share Capital	940	940	940	862	781
Total Reserves	2,482	1,941	1,620	1,309	393
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	118	100	87	78	77
Other Current Liabilities	77	63	69	28	58
Short Term Borrowings	46	725	832	578	125
Total Liabilities	4,158	4,069	3,778	3,082	1,839
Capital Work in Progress	---	---	256	62	2
Long Term Loans & Advances	12	10	23	22	62
Currents Investments	892	637	623	414	---
Short Term Loans and Advances	301	196	96	82	175
Total Current Assets	2,724	2,770	1,817	1,398	865
Total Assets	4,158	4,069	3,778	3,082	1,839
Adjusted Book Value	4	3	3	3	2

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 22.49, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a moderate 3-year price CAGR of 14.9%, reflecting average market performance.
The stock carries a high beta of 1.4, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹716 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹4650 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 703747.8

No. of Shares: 59488 (Approx)

Performance:-29.6%

P/L: ₹-296252.2

NIFTY Performance: 9.7%

1 day Top Gainers